LEO Pharma Annual Results 2018: A Year in Line with Expectations

February 28, 2019 |

1 min read

LEO Pharma A/S announced its annual results for 2018 and outlined expectations for 2019.

Feb. 28, 2019 08:29 UTC

2018 revenue of DKK 10,410 million
Strong progress on 2025 Strategy
Strengthened innovative clinical pipeline
Expanded established portfolio

BALLERUP, Denmark--(BUSINESS WIRE)-- Today, LEO Pharma A/S announced its annual results for 2018 and outlined expectations for 2019.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190228005322/en/

“We have set ourselves ambitious goals to make a true difference in the lives of people living with skin diseases. 2018 has been yet another eventful year on this pioneering journey, as we have strengthened LEO Pharma’s foothold in medical dermatology significantly. We are pleased to present the 2018 results which are satisfactory and in line with expectations and will help us further drive scientific advancements, and bring much-needed progress for patients,” said Gitte P. Aabo, CEO and President of LEO Pharma.

LEO Pharma’s consolidated revenue amounted to DKK 10,410 million in 2018, a level similar to revenue in 2017 (DKK 10,481 million).

Operating profit increased from DKK 852 million in 2017 to DKK 1,605 million in 2018. The increase in operating profit was predominantly driven by the strategic decision to divest LEO Pharma’s non-strategic derma portfolio to Karo Pharma AB. The divestment resulted in a net gain of DKK 1,566 million recognized as other operating income.

Key figures	2017	2018	Change in %
Revenue (DKK million)	10,481	10,410	-1%
Operating profit (DKK million)	852	1,605	88%
Investments in R&D (% of Revenue)	15%	18%	3%